0DPB.LSE

Bavarian Nordic A/S

0DPB.LSE, UK

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

https://www.bavarian-nordic.com

Stock Price

DKK0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2023-09-30)

Health Score

Investors

* Institutions hold a combined 0.00% of the total shares of Bavarian Nordic A/S

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

13.9625

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2023-09-30)

Deep Value
Weak Deep Value(0.5)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(1.5)
GARP
Not Attractive for GARP(0)
Growth
Weak Growth Prospect(0)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(0)
Quality
Low Quality Business(0.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2023-09-30)

Revenue

DKK 0

Cost Of Revenue

DKK 0

Gross Profit

DKK 0

Operating Expenses

DKK 0

Operating Income

DKK 0

Interest Expense

DKK 0

Pretax Income

DKK 0

Net Income

DKK 0

Income Tax Expense

DKK 0

EBITDA

DKK 0

Total Other Income Expense Net

DKK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2023-09-30)

Cash

DKK 0

Short Term Investments

DKK 0

Receivables

DKK 0

Inventories

DKK 0

Total Current Assets

DKK 0

Property Plant Equipment

DKK 0

Total Assets

DKK 0

Payables

DKK 0

Short Term Debt

DKK 0

Long Term Debt

DKK 0

Total Liabilities

DKK 0

Equity

DKK 0

Trend

Cash Flow

(Last Updated 2023-09-30)

Net Income

DKK 0

Depreciation

DKK 0

Change In Working Capital

DKK 0

Cash From Operations

DKK 0

Capital Expenditures

DKK 0

Cash From Investing

DKK 0

Cash From Financing

DKK 0

Net Change In Cash

DKK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.